Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minoxidil

This article was originally published in The Tan Sheet

Executive Summary

Foam delivery system for OTC hair loss treatment ingredient under development, Palo Alto, Calif.-based Connetics says in teleconference March 21. Firm may commercialize product itself or seek marketing partners; Rogaine marketer Pharmacia says it currently has no interest in alternative delivery forms. Connetics also developing foam delivery for ketoconazole 2% and plans to file an NDA during first half of 2002 upon completing clinical trial this year; the 2% dose (McNeil's Rx Nizoral) recently was associated with hair loss benefits, prompting McNeil to investigate a new indication (1"The Tan Sheet" March 12, p. 3). Connetics acquired Victoria, Australia-based Soltec Research for $16.9 mil. in cash March 20. Soltec developed a mousse delivery form for Bayer's Rid pediculicide approved March 2000

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel